HIGHLIGHTS
- who: Ola Landgren from the Memorial Sloan Kettering Cancer Center, New York, NY, USA have published the article: Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma, in the Journal: (JOURNAL)
- what: The aim of this review was to describe efficacy and safety data for carfilzomib-based PI/immunomodulatory combinations in NDMM.
SUMMARY
In ASPIRE and ENDEAVOR, treatment with carfilzomib-based regimens (ASPIRE: carfilzomib-lenalidomide-dexamethasone; ENDEAVOR: carfilzomib-dexamethasone ) resulted in superior PFS, OS, depth of response, and healthrelated quality of life (QoL) versus recent standards of care . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.